Merck
Merck Suspends Gardasil Shipments to China, Lowers 2025 Revenue Forecast
Merck, Gardasil, China, revenue forecast, cancer vaccine, shipment suspension
RFK Jr.’s Financial Ties to Gardasil Litigation Spark Conflict-of-Interest Concerns
RFK Jr., Gardasil, Merck, Conflict of Interest, Vaccine Litigation, HHS Secretary Nomination
WuXi Biologics Divests Irish Vaccine Facility to Merck for $500 Million Amid Strategic Shift
WuXi Biologics, Merck, vaccine manufacturing facility, Dundalk, Ireland, asset sale, strategic shift, regulatory changes, Biosecure Act
Merck Acquires WuXi Biologics’ Irish Vaccine Facility in $500M Deal
Merck, WuXi Biologics, vaccine facility, Ireland, $500M deal, pharmaceutical manufacturing
Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug
Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits
Merck Discontinues TIGIT and LAG-3 Programs Amid Efficacy Concerns
Merck, TIGIT, LAG-3, Keytruda, Cancer Therapy, Clinical Trials
Merck and Kelun-Biotech Advance in Cancer Treatment with Exclusive License Agreement for Investigational ADC Candidates
Merck, Kelun-Biotech, Antibody-Drug Conjugates (ADC), Cancer Treatment, Exclusive License Agreement, TROP2, Nectin-4, SKB571
Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study
Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality
Merck’s Subcutaneous Keytruda Shows Non-Inferiority in Phase 3 Trial, Paving Way for Regulatory Discussions
Merck, Keytruda, subcutaneous, cancer immunotherapy, phase 3 trial, non-inferiority, regulatory submissions
Merck’s Gardasil Sales in China Continue to Decline Amid Economic and Regulatory Challenges
Merck, Gardasil, China, vaccine sales, economic challenges, regulatory issues